Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403191 | 0.98 | SMN1; SMN2 (0.33) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL403250 | 0.90 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL30623393 | 0.89 | LMNA (0.32) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL30721455 | 0.84 | — | — | |
| SCHEMBL21460515 | 0.81 | LMNA (0.36) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL7215321 | 0.81 | LMNA (0.36) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL10440035 | 0.81 | LMNA (0.36) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL30623396 | 0.79 | — | — | |
| SCHEMBL12737502 | 0.79 | — | — | |
| SCHEMBL6553343 | 0.78 | SMN1; SMN2 (0.33) | LMNAALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101701-B2 | having a hydrophilic group and a silicon-containing alkyl group within molecule; lenses with high oxygen permeability independent from the water content may be obtained, wherein the fumaric acid derivatives is superior in compatibility with the hydrophilic monomer used in combination | MENICON NECT CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| EP-1930338-A1 | Fumaric acid derivates and ophtalmic lenses using the same | E-brain Corporation Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | MENICON NECT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132666-A1 | Fumaric Acid Derivatives and Ophthalmic Lenses Using the Same | FAH, FH, AQP4 | LMNA 3082/4885ALDH1A1 741/4885HSD17B10 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.